Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
AssigneesRegeneron Pharmaceuticals, Inc., Sanofi Biotechnology
InventorsJennifer D. HAMILTON, Jennifer MALONEY, Leda MANNENT, Marcella RUDDY
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for treating, preventing, or ameliorating one or more symptoms of eosinophilic esophagitis in an adolescent or adult subject by administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) inhibitor, such as an anti-IL-4R antibody or antigen-binding fragment thereof.
Claims42
A method of treating, preventing, or ameliorating at least one symptom of eosinophilic esophagitis (EoE) in a subject≥12 years of age, the method comprising administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) inhibitor, wherein prior to the onset of treatment the subject has a Dysphagia Symptom Questionnaire (DSQ) score≥10, and wherein the IL-4R inhibitor is an antibody or antigen-binding fragment thereof that binds IL-4Rα and comprises a heavy chain complementarity determining region (HCDR)1 comprising the amino acid sequence of SEQ ID NO:3, an HCDR2 comprising the amino acid sequence of SEQ ID NO:4, an HCDR3 comprising the amino acid sequence of SEQ ID NO:5, a light chain complementarity determining region (LCDR)1 comprising the amino acid sequence of SEQ ID NO:6, an LCDR2 comprising the amino acid sequence of SEQ ID NO:7, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:8.
19-27. (canceled)
A method of improving the ability to swallow food in a subject, the method comprising:
- administering to a subject having eosinophilic esophagitis (EoE) one or more doses of an interleukin-4 receptor (IL-4R) inhibitor, wherein the IL-4R inhibitor is an antibody or antigen-binding fragment thereof that binds IL-4Rα and comprises a heavy chain complementarity determining region (HCDR)1 comprising the amino acid sequence of SEQ ID NO:3, an HCDR2 comprising the amino acid sequence of SEQ ID NO:4, an HCDR3 comprising the amino acid sequence of SEQ ID NO:5, a light chain complementarity determining region (LCDR)1 comprising the amino acid sequence of SEQ ID NO:6, an LCDR2 comprising the amino acid sequence of SEQ ID NO:7, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:8.
The method of 28, wherein the IL-4R inhibitor is administered at a dose of about 50 mg to about 600 mg.
(canceled)
(canceled)
Dependencies are inferred from the claim text.